Apotea AB (publ) (APOTEA.ST) Stock Price

Apotea AB (publ) Price

CLOSED
92.15
​
Market closed

Over the last 4 years Apotea AB (publ) grew revenue by 12.1% annually, reaching 7.20 B SEK. Earnings per share have grown at 21.6% per year over the last 4 years. For Apotea AB (publ), the net margin of 3.2% is broadly stable versus 2.3% a few years ago. The consensus 12-month price target for Apotea AB (publ) is 100.98 SEK, about 9.6% above where the stock trades today. Of 6 analysts, 4 rate the stock a buy — an overall Buy consensus.

Apotea AB (publ) stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Apotea AB (publ) business model & stock analysis

Apotea AB (publ) is a publicly listed company based in Stockholm, Sweden, operating within the Consumer Staples sector, specifically in the Retail industry. The company provides an online pharmacy service offering both non-prescription and prescription medications, alongside wholesale trade of cosmetics, general drugs, and other pharmacy-related products. Apotea AB (publ) has a workforce of 725 full-time employees. The company completed its initial public offering (IPO) on December 6, 2024, and is listed on the Stockholm Stock Exchange under the ticker symbol APOTEA.ST. Its official website is www.apotea.se. Apotea AB (publ) operates through a combination of online platforms and physical retail locations, delivering pharmacy services directly to consumers. The company's business model integrates digital commerce with traditional retail, focusing on accessibility and convenience for customers seeking pharmaceutical and cosmetic products. Apotea AB (publ) is headquartered in Stockholm, Sweden, and serves customers primarily within the Swedish market. The company's operations are centered around providing a comprehensive range of pharmacy-related products and services, emphasizing both online and offline retail channels.

Frequently asked questions about Apotea AB (publ)

Analysts currently set an average price target of 100.98 SEK for the Apotea AB (publ) stock (median: 100.98 SEK), implying +9.6 % versus the latest price. The consensus is based on 6 analyst ratings.

6 analysts currently rate the Apotea AB (publ) stock: 4 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Apotea AB (publ) to generate revenue of 8.06 B SEK and earnings per share of 2.80 SEK.

Converted at the current exchange rate, the Apotea AB (publ) share trades at 8.40 EUR (92.15 SEK).

The expected revenue of Apotea AB (publ) is 8.06 B SEK. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Apotea AB (publ) is 291.80 M SEK. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Apotea AB (publ) is currently 32.87. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Apotea AB (publ) stock.

The price-to-sales ratio (P/S) of Apotea AB (publ) is currently 1.19. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Apotea AB (publ) stock.

The Eulerpool Quality Score for Apotea AB (publ) is 7/10.

The ISIN of Apotea AB (publ) is SE0023313762. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Apotea AB (publ) is APOTEA.ST. The ticker symbol is used to trade Apotea AB (publ) shares on the stock exchange.

Fair ValueTerminal
89.39 SEK
Over-/UndervaluationTerminal
Fairly valued
Industry
Consumer Staples Distribution & Retail
Number of shares
Employees
Revenue per Employee
9.94 M SEK
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website apotea.se
Country
Sweden
Currency
SEK
Initial public offering
Dec 6, 2024
ISIN
SE0023313762
Cusip
W05022111
Market capitalization
9.59 B SEKMid Cap
52-Week Range
PEG
3.03
P/E ratio
P/Ee 2026
32.88
P/Ee 2027
26.31
P/Ee 2028
22.30
P/S
P/Se
1.19
EV/EBIT
32.57
P/B Ratio
11.37
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
19.46 %
Last updated Nov 1, 2026, 6:38 AM

Apotea AB (publ) Peer Group